Cullinan presents initial Phase 1 CLN-978 data in refractory RA, SLE at EULAR 2026

• Cullinan Therapeutics flagged initial Phase 1 findings for its subcutaneous CD19xCD3 T-cell engager CLN-978 in treatment-refractory rheumatoid arthritis and systemic lupus erythematosus, with results set for presentation at the EULAR 2026 congress in London on June 6, 2026.
• Early readouts from the OUTRACE RA and OUTRACE SLE studies indicated a favorable safety profile at the first dose levels.
• The studies also showed robust depletion of B cells in blood and tissue, with early signs of clinical activity in both diseases.
• The EULAR presentation is expected to include additional patients beyond the already published abstract, keeping near-term focus on whether the signal holds as enrollment expands.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cullinan Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605181700PRIMZONEFULLFEED9722500) on May 18, 2026, and is solely responsible for the information contained therein.